Skip to main content

SeaStar Medical Holding Corp

corporate_fare Company Profile

SeaStar Medical Holding Corp

ICU·NASDAQ·Industrial Applications And Services·CIK 0001831868

SeaStar Medical is a commercial-stage healthcare company developing treatments for critically ill patients experiencing organ failure. The company's primary product is the Selective Cytopheretic Device ("SCD"), a device designed to neutralize over-active immune cells and stop cytokine storms that cause hyperinflammation. The SCD has potential applications for patients with acute and chronic kidney disease, cardiovascular disease, and other inflammatory conditions. On February 21, 2024, SeaStar Medical received Food and Drug Administration ("FDA") approval under a Humanitarian Device Exemption ("HDE") for its pediatric SCD therapy. This product, branded "QUELIMMUNE," is the only FDA-approved product for pediatric patients with acute kidney injury ("AKI") due to sepsis or a septic condition requiring kidney replacement therapy. The first commercial pediatric SCD was shipped in July 2024. The company is also conducting a pivotal clinical trial, "NEUTRALIZE-AKI," to evaluate the safety and efficacy of SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy ("CRRT"). Additionally, a feasibility study is underway for SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation. The FDA has granted six Breakthrough Device Designations ("BDD") for the SCD therapy, covering multiple indications in adult patients, including AKI, CRS awaiting LVAD implantation, hepatorenal syndrome, end-stage renal disease ("ESRD"), and systemic inflammatory response during cardiac surgery.

SeaStar Medical Holding Corp (NASDAQ:ICU) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 25 items for ICU at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • SeaStar Medical Secures Dismissal of Class Action Lawsuit
  • Annual Report Highlights Improved Financials & Clinical Progress Amidst Persistent Going Concern Risk
  • SeaStar Medical's 2025 Revenue Surges to $1.2M, Annual Loss Narrows to $12.2M on Strong Product Adoption
  • SeaStar Medical Reports Strong 2025 Financials with Surging Revenue, Reduced Loss, and Major Clinical Milestones
  • SeaStar Medical Regains Nasdaq Minimum Bid Price Compliance, Averting Delisting Risk

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.23M
Net Income
-$12.15M
Op. Cash Flow
-$13.6M
Gross Profit
$1.18M
Operating Income
-$12.18M
Cash & Equivalents
$11.98M
Debt / Equity
0.00×
Net Margin
-9.85×
Shares Outstanding
3.84M sh
Source: 10-K · filed 2026-03-25 · accession 0001437749-26-009797
$0.8919 -4.61% today
52-week range · as of 2026-11-20 $0.761 – $5.38
Market cap
$4.97M
Volume
135.8K (0.5× avg)
3-mo avg 276.8K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ICU - Filings & News (Page 2)

ICU
Apr 28, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.92
Real-time Price: $0.8919 info
Change: -$3.03 (-77%) info
Market Cap: $4.97M info
ICU
Mar 25, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $0.8919 info
Change: -$1.51 (-63%) info
Market Cap: $4.97M info
ICU
Mar 25, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.30
Real-time Price: $0.8919 info
Change: -$1.41 (-61%) info
Market Cap: $4.97M info
ICU
Mar 25, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $0.8919 info
Change: -$1.41 (-61%) info
Market Cap: $4.97M info
ICU
Jan 20, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $0.8919 info
Change: -$1.39 (-61%) info
Market Cap: $4.97M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets